AWAK Technologies Raises US$40million in oversubscribed fund raise

  • We are excited to announce that we have raised US$40 million of new funds in an oversubscribed financing round to ready our wearable and ultra-portable AWAK Peritoneal Dialysis (AWAK PD) device for late-stage clinical studies and to accelerate our commercialisation plans.

“Currently, around three million people are undergoing dialysis treatment and forced to adapt their lifestyle to the therapy. AWAK PD aims to provide dialysis on-the-go with maximum convenience and comfort, reducing the time and cost burdens of dialysis for patients and healthcare systems alike”, said Suresha Venkataraya, CEO of AWAK.

The investment round was co-led by Vickers Venture Partners, a leading venture capital firm focused on life sciences and deep tech, and a leading global medical products company. Shares were also subscribed by other new investors and existing investors including Advanced MedTech and Enterprise Singapore’s investment arm SEEDS Capital.

For more details on the fund raise and what our shareholders are saying, please read our Press Release here:

AWAK PD Device Granted US FDA Breakthrough Device Designation

AWAK – world’s first wearable PD device shown to be safe

AWAK Strengthens Presence in Singapore with New Headquarters

© 2020 AWAK Technologies. All Rights Reserved.